Evidence map›Paper›PMID 35522290›Full record

ArticleJournal of cancer research and clinical oncology2022

The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy.

Man Yi Li, Le Mi, Gennady Meerovich, Thin Wut Soe, Ting Chen, Ni Ni Than, Yi Jia Yan, Zhi Long Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Synthesis and Evaluation of NovelACS medicinal chemistry letters · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Man Yi LiDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China.
Le MiDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China.
Gennady MeerovichProkhorov General Physics Institute of the Russian Academy of Sciences, Moscow, 119435, Russia.
Thin Wut SoeDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China.
Ting ChenDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China.
Ni Ni ThanDepartment of Chemistry, University of Yangon, Yangon, 11041, Myanmar.
Yi Jia YanDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China. y_yan11@sina.com.
Zhi Long ChenDepartment of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai, 201620, China. zlchen1967@qq.com.ORCID http://orcid.org/0000-0001-9716-8368
Donghua University · CNProkhorov General Physics Institute · RUUniversity of Yangon · MM

Funding

Foundation of Shanghai Science and Technology Committee 19410711000Foundation of Shanghai Science and Technology Committee 20430730900Foundation of Shanghai Science and Technology Committee 20490740400Foundation of Shanghai Science and Technology Committee 21430730100National Natural Science Foundation of China 21977016
6 · The paper itself

Abstract

purposeEsophageal cancer is the most common gastrointestinal tumor and is difficult to be eradicated with conventional treatment. Porphyrin-based photosensitizers (PSs) mediated photodynamic therapy (PDT) could kill tumor cells with less damage to normal cells. As the most widely used porphyrin-based photosensitizer in clinics, Photofrin II has excellent anti-tumor effect. However, it has some disadvantages such as weak absorption at near infrared region, the complexity of components and prolonged skin photosensitivity. Here series novel 5,15-diaryl-10,20-dihalogeno porphyrin derivatives were afforded and evaluated to develop more effective and safer photosensitizers for tumor therapy.

methodsThe photophysical properties and singlet oxygen generation rates of 5,15-diaryl-10,20-dihalogeno porphyrins (I

results5,15-Diaryl-10,20-dihalogeno porphyrins I

conclusionAll new compounds have obvious photodynamic anti-esophageal cancer effects. Among them, the photosensitizer II

Indexed as

Antineoplastic AgentsEsophageal NeoplasmsPhotochemotherapyPorphyrinsAnimalsCell Line, TumorMiceMice, NudePhotosensitizing AgentsSinglet OxygenAntineoplastic AgentsPhotosensitizing AgentsPorphyrinsSinglet OxygenAnti-tumorHalogenated porphyrinPhotodynamic therapyPhotosensitizer

Identifiers

PMID35522290
PMCPMC11800913
OpenAlexW4229040116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.